Johnson & Johnson $JNJ Shares Sold by Truist Financial Corp

Truist Financial Corp trimmed its stake in shares of Johnson & Johnson (NYSE:JNJ) by 2.0% in the second quarter, Holdings Channel reports. The fund owned 1,554,159 shares of the company’s stock after selling 32,198 shares during the period. Truist Financial Corp’s holdings in Johnson & Johnson were worth $237,398,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in JNJ. Elios Financial Group Inc. grew its position in Johnson & Johnson by 1.5% during the first quarter. Elios Financial Group Inc. now owns 4,496 shares of the company’s stock valued at $746,000 after acquiring an additional 66 shares during the period. Atlantic Family Wealth LLC grew its position in Johnson & Johnson by 4.4% during the first quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company’s stock valued at $266,000 after acquiring an additional 67 shares during the period. MBA Advisors LLC grew its position in Johnson & Johnson by 1.2% during the first quarter. MBA Advisors LLC now owns 5,553 shares of the company’s stock valued at $921,000 after acquiring an additional 68 shares during the period. Sovereign Financial Group Inc. grew its position in Johnson & Johnson by 1.8% during the first quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company’s stock valued at $651,000 after acquiring an additional 69 shares during the period. Finally, Nabity Jensen Investment Management Inc grew its position in Johnson & Johnson by 1.5% during the first quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company’s stock valued at $767,000 after acquiring an additional 69 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on JNJ shares. Wall Street Zen raised Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. The Goldman Sachs Group upped their target price on Johnson & Johnson from $185.00 to $186.00 and gave the stock a “buy” rating in a research report on Friday, September 19th. Erste Group Bank raised Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Wednesday, July 23rd. Royal Bank Of Canada upped their target price on Johnson & Johnson from $181.00 to $185.00 and gave the stock an “outperform” rating in a research report on Thursday, July 17th. Finally, Morgan Stanley upped their target price on Johnson & Johnson from $171.00 to $176.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 17th. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $181.40.

Johnson & Johnson Trading Up 0.3%

NYSE:JNJ opened at $185.99 on Thursday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. Johnson & Johnson has a one year low of $140.68 and a one year high of $186.56. The business’s 50-day simple moving average is $175.45 and its 200 day simple moving average is $162.51. The stock has a market cap of $447.92 billion, a price-to-earnings ratio of 19.89, a price-to-earnings-growth ratio of 2.36 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business had revenue of $23.74 billion for the quarter, compared to analysts’ expectations of $22.85 billion. During the same quarter in the previous year, the firm posted $2.82 earnings per share. The company’s revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were paid a $1.30 dividend. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 2.8%. Johnson & Johnson’s payout ratio is 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.